Larimar Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.85
- Today's High:
- $4.08
- Open Price:
- $3.85
- 52W Low:
- $2.58
- 52W High:
- $6.85
- Prev. Close:
- $3.82
- Volume:
- 76538
Company Statistics
- Market Cap.:
- $165.75 million
- Book Value:
- 2.309
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -25.93%
- Return on Equity TTM:
- -43.52%
Company Profile
Larimar Therapeutics Inc had its IPO on 2014-06-19 under the ticker symbol LRMR.
The company operates in the Healthcare sector and Biotechnology industry. Larimar Therapeutics Inc has a staff strength of 26 employees.
Stock update
Shares of Larimar Therapeutics Inc opened at $3.85 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.85 - $4.08, and closed at $4.01.
This is a +4.97% increase from the previous day's closing price.
A total volume of 76,538 shares were traded at the close of the day’s session.
In the last one week, shares of Larimar Therapeutics Inc have increased by +4.7%.
Larimar Therapeutics Inc's Key Ratios
Larimar Therapeutics Inc has a market cap of $165.75 million, indicating a price to book ratio of 1.6336 and a price to sales ratio of 0.
In the last 12-months Larimar Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-35900000. The EBITDA ratio measures Larimar Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Larimar Therapeutics Inc’s operating margin was 0% while its return on assets stood at -25.93% with a return of equity of -43.52%.
In Q2, Larimar Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Larimar Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.74 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Larimar Therapeutics Inc’s profitability.
Larimar Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.1441. Its price to sales ratio in the trailing 12-months stood at 0.
Larimar Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $111.72 million
- Total Liabilities
- $7.28 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Larimar Therapeutics Inc ended 2024 with $111.72 million in total assets and $0 in total liabilities. Its intangible assets were valued at $111.72 million while shareholder equity stood at $99.93 million.
Larimar Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $7.28 million in other current liabilities, 43000.00 in common stock, $-166497000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $94.32 million and cash and short-term investments were $104.20 million. The company’s total short-term debt was $566,000 while long-term debt stood at $0.
Larimar Therapeutics Inc’s total current assets stands at $106.48 million while long-term investments were $0 and short-term investments were $9.88 million. Its net receivables were $0 compared to accounts payable of $2.34 million and inventory worth $0.
In 2024, Larimar Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Larimar Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $4.01
- 52-Week High
- $6.85
- 52-Week Low
- $2.58
- Analyst Target Price
- $11.88
Larimar Therapeutics Inc stock is currently trading at $4.01 per share. It touched a 52-week high of $6.85 and a 52-week low of $6.85. Analysts tracking the stock have a 12-month average target price of $11.88.
Its 50-day moving average was $3.67 and 200-day moving average was $4.3 The short ratio stood at 1.54 indicating a short percent outstanding of 0%.
Around 162.9% of the company’s stock are held by insiders while 8896.4% are held by institutions.
Frequently Asked Questions About Larimar Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.